Ovarian Cancer Detection
Ovarian cancer is the fourth leading cause of cancer death in women. When diagnosed early, ovarian cancer has a 5-year survival rate of greater than 90%. However, more than 80% of patients are diagnosed at a late stage when even aggressive treatment with surgery and chemotherapy are unable to stop the cancer.
Despite large scale investigations into screening, the National Cancer Institute sponsored Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial concluded, “annual screening for ovarian cancer as performed in the PLCO trial with simultaneous CA-125 and transvaginal ultrasound does not reduce disease-specific mortality in women at average risk for ovarian cancer.“ (JAMA. 2011; 305(22):2273-2276)
Any advance that can accurately detect ovarian cancer in its early stage can have a great impact on overall survival. We hypothesize that the odors emanating from ovarian tissue will provide a reliable, detectable substrate for early detection, allowing more effective treatment. We are now looking at odors emanating from blood samples of patients with ovarian cancer.
This project will compare the ability of canine and other sensors to detect the unique signature of serum samples from ovarian cancer versus control patients. We also aim to identify what specifically distinguishes diseased from healthy samples. In addition, we will determine which sample type (serum, vaginal secretions, urine or exhaled air) is most effective and accurate for screening.
Ovarian Cancer Symptom Awareness Organization is funding a 2015 Summer Research Intern to work on this research project. Application details coming soon!
1. Determine the sensitivity and specificity of dogs in detecting and distinguishing plasma samples from patients with ovarian cancer versus patients with benign gynecologic growths and healthy controls.
2. Identify the type and relative amounts of the volatile organic compounds which distinguish diseased from non-diseased plasma samples.
3. Test whether or not the target volatile organic compounds emanating from plasma samples is what is identified by the dogs.
4. Develop an electronic sensor array platform that will serve as the front end of a prototype e-nose system to be used in ovarian cancer detection.
- George Preti, PhD (Principle Investigator) – Monell Chemical Senses Center
- Cindy Otto, DVM, PhD – Penn Vet Working Dog Center
- Janos Tanyi, MD, PhD – Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania
- A.T. Charlie Johnson, PhD – Department of Physics and Astronomy, University of Pennsylvania
- Jody Piltz-Seymour, MD – Perelman School of Medicine, University of Pennsylvania